Prices that used to hide in the shadows are stepping into the light—and it’s changing how patients get their medicines. We dive deep into the PBM reckoning: why scrutiny is mounting, how California’s new law opens the books on rebates and reimbursements, and what more than 30 states signal for the future of drug access. From there, we chart the path pharma is taking to meet the moment—standing up direct-to-consumer channels, publishing clear cash prices for GLP-1s and insulin, and using digital tools to support patients at the exact moment they need guidance.We unpack the incentives that got us here—spread pricing, formulary gatekeeping, and opaque negotiations—and then show how transparency reshapes behavior across the board. When a payer can see a cash price, the math behind rebates changes. When a patient can tap a support team, dose questions and refills don’t become barriers. And when adherence and symptom data flow securely into connected systems, trial churn falls and real-world evidence grows stronger. It’s not just a commercial pivot; it’s an outcomes strategy that relies on timely education, affordability support, and trust built one interaction at a time.You’ll hear a clear game plan for leaders across pharma: align patient support, access, IT/security, and procurement around HIPAA-compliant, interoperable platforms; embed copay and affordability tools where decisions happen; and design companion experiences early so launches are patient-ready on day one. Over the next two to three years, transparency will be a differentiator, D2C will scale fast, and “digital” will simply be how care is coordinated. If you’re ready to lead in a post-PBM landscape—and prove it with measurable results—hit play, subscribe, and share your take. Your feedback helps us spotlight what’s working and where the industry should go next.PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.

Ver todos los episodios